脂肪原/磷菌素/AG-CN2-0057-C010/10微克
商品编号：
AG-CN2-0057-C010
品牌：
Adipogen Inc
市场价：
¥3100.00
美元价：
1860.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| ProductDetails | |
|---|---|
| Synonyms | Phosphotrienin;CI-920;CL-1565A;NSC-339638;PD110,161;Pyranonephosphate |
| ProductType | Chemical |
| Properties | |
| Formula | C19H26O9PNa |
| MW | 452.4 |
| CAS | 87860-39-7 |
| RTECS | UQ0600000 |
| Source/HostChemicals | IsolatedfromStreptomycespulveraceoussubsp.fostreus. |
| PurityChemicals | ≥98%(HPLC) |
| Appearance | Colorlesssolid. |
| Solubility | Solubleinwater,methanolorethanol. |
| OtherProductData | Useonlyfreshsolutions. |
| InChiKey | XBUIKNRVGYFSHL-CZYWAGOEBB |
| ShippingandHandling | |
| Shipping | AMBIENT |
| ShortTermStorage | +4°C |
| LongTermStorage | -20°C |
| HandlingAdvice | Hygroscopic. Keepcoolanddry. |
| Use/StABIlity | Stableforatleast2yearsafterreceiptwhenstoredat-20°C. |
| Documents | |
| MSDS |  DownloadPDF |
| ProductSpecificationSheet | |
| Datasheet | DownloadPDF |
- Antibiotic[1,2,18].
- Anticancercompound[1-5,8,9,11].
- Antifungal[6].
- CatalyticinhibitoroftopoisomeraseII(IC50=40μM)[7,16].
- Potentproteinphosphatase2A(PP2A)(IC50=1.5nM)and4(PP4)(IC50=3nM)inhibitor[10,12,15].
- Weakproteinphosphatasetype1(PP1)inhibitor(IC50=131µM).NoapparentinhibitiononPP2B[10,12].
- Mitoticentrycheckpointinhibitor[10].MediatescellcyclearrestatG2-M-phase[14].
- Ischemiaprotective[13].
- ThePP2Abindingsiteisdifferentfromthatofokadaicacid[17,19]
ProductReferences
- NovelantitumoragentsCI-920,PD113,270andPD113,271.I.Taxonomy,fermentationandBIOLOGicalproperties:J.B.Tunac,etal.;J.Antibiot.(Tokyo)36,1595(1983)
- NovelantitumoragentsCI-920,PD113,270andPD113,271.II.Isolationandcharacterization:S.S.Stampwala,etal.;J.Antibiot.(Tokyo)36,1601(1983)
- Studiesonthebiochemicalmechanismofthenovelantitumoragent,CI-920:D.W.Fry,etal.;CancerChemother.Pharmacol.13,171(1984)
- AnticanceractivityofthestructurallynovelantibioticCl-920anditsanalogues:W.R.Leopold,etal.;CancerRes.44,1928(1984)
- Invitroactivityofthenovelantitumorantibioticfostriecin(CI-920)inahumantumorcloningassay:W.Scheithauer,etal.;Eur.J.CancerClin.Oncol.22,921(1986)
- Antimycoticeffectsofthenovelantitumoragentsfostriecin(CI-920),PD113,270andPD113,271:S.W.Mamber,etal.;J.Antibiot.(Tokyo)39,1467(1986)
- InhibitionoftypeIItopoisomerasebyfostriecin:T.J.Boritzki,etal.;Biochem.Pharmacol.37,4063(1988)
- CytostaticandcytotoxiceffectsoffostriecinonhumanpromyelocyticHL-60andlymphocyticMOLT-4leukemiccells:M.A.Hotz,etal.;CancerRes.52,1530(1992)
- ChangesinnuclearchromatinrelatedtoapoptosisornecrosisinducedbytheDNAtopoisomeraseIIinhibitorfostriecininMOLT-4andHL-60cellsarerevealedbyalteredDNAsensitivitytodenaturation:M.A.Hotz,etal.;Exp.CellRes.201,184(1992)
- Antitumordrugfostriecininhibitsthemitoticentrycheckpointandproteinphosphatases1and2A:M.Roberge,etal.;CancerRes.54,6115(1994)
- Fostriecin:areviewofthepreclinicaldata:R.S.deJong,etal.;AnticancerDrugs8,413(1997)
- Fostriecin,anantitumorantibioticwithinhibitoryactivityagainstserine/threonineproteinphosphatasestypes1(PP1)and2A(PP2A),ishighlyselectiveforPP2A:A.H.Walsh,etal.;FEBSLett.416,230(1997)
- Fostriecin,aninhibitorofproteinphosphatase2A,limitsmyocardialinfarctsizeevenwhenadmiNISTeredafteronsetofischemia:C.Weinbrenner,etal.;Circulation98,899(1998)
- Fostriecin-mediatedG2-M-phasegrowtharrestcorrelateswithabnormalcentrosomereplication,theformationofaberrantmitoticspindles,andtheinhibitionofserine/threonineproteinphosphataseactivity:A.Cheng,etal.;CancerRes.58,3611(1998)
- Purificationofproteinphosphatase4catalyticsubunit:inhibitionbytheantitumourdrugfostriecinandothertumoursuppressorsandpromoters: C.J.Hastie&P.T.Cohen;FEBSLett.431,357(1998)
- PhaseIandpharmacokineticstudyofthetopoisomeraseIIcatalyticinhibitorfostriecin:R.S.deJong,etal.;Br.J.Cancer79,882(1999)
- Thepredictedbeta12-beta13loopisimportantforinhibitionofPP2Acalphabytheantitumordrugfostriecin:D.R.Evans&J.A.Simon;FEBSLett.498,110(2001)
- Fostriecin:chemistryandbiology:D.S.Lewy,etal.;Curr.Med.Chem.9,2005(2002)
- Antitumorantibioticfostriecincovalentlybindstocysteine-269residueofproteinphosphatase2Acatalyticsubunitinmammaliancells:T.Takeuchi,etal.;Bioorg.Med.Chem.17,8113(2009)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
